Abstract
Multiple myeloma (MM) continues to evade cure by conventional therapies, increasing the urgency for new, biologically based treatments. Reviewed in this discussion are novel chemotherapies under clinical trial that capitalize upon greater comprehension of tumor pathophysiology. In targeting tumor biology, these therapies serve as a model of treatment with great potential for improving outcomes in patients with MM.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
2-Methoxyestradiol
-
Angiogenesis Inhibitors / therapeutic use
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Arsenic Trioxide
-
Arsenicals / therapeutic use
-
Cysteine Endopeptidases
-
Enzyme Inhibitors / therapeutic use
-
Estradiol / analogs & derivatives
-
Estradiol / therapeutic use
-
Humans
-
Multienzyme Complexes / antagonists & inhibitors
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / pathology
-
Oxides / therapeutic use
-
Proteasome Endopeptidase Complex
-
Thalidomide / analogs & derivatives
-
Thalidomide / therapeutic use
-
Tissue Extracts / therapeutic use
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Arsenicals
-
Enzyme Inhibitors
-
Multienzyme Complexes
-
Oxides
-
Tissue Extracts
-
shark cartilage extract
-
Estradiol
-
Thalidomide
-
2-Methoxyestradiol
-
Cysteine Endopeptidases
-
Proteasome Endopeptidase Complex
-
Arsenic Trioxide